Studies Reporting on Tumor-Absorbed Dose vs. Response in Microsphere Radioembolization of Hepatic Malignancies
| Study | n | Disease | Lesion size (cm) | Device | Imaging | Endpoint | Threshold mean dose (Gy) |
|---|---|---|---|---|---|---|---|
| Garin (92,127,128) | 36, 71, 71 | HCC | 7.1 ± 3.3 | 90Y glass | 99mTc-MAA SPECT | PFS, EASL | 205 |
| Mazzaferro (129) | 52 | HCC | 90Y glass | 99mTc-MAA SPECT | EASL (PR + CR) | 500 | |
| Chiesa (130) | 52 | HCC | 4.9 (1.8–10.3) | 90Y glass | 99mTc-MAA SPECT | EASL (PR + CR) 50% TCP | 390 |
| Chan (131) | 35 | HCC | 7.3 (3.0–17.9) | 90Y glass | 90Y PET/CT | mRECIST (PR + CR) | 200 |
| Ho (132) | 62 | HCC | 90Y glass | 99mTc-MAA SPECT/CT | 18F-FDG, 11C PET res. > 50% | 170 | |
| Kappadath (110) | 34 | HCC | 4.1 (2.6–12.3) | 90Y glass | 90Y SPECT/CT | mRECIST 50% TCP | 160 |
| Dewaraja (111) | 28 | HCC and metastases | 2.7 (1.6–11.7) | 90Y glass | 90Y PET/CT | mRECIST 50% TCP | 290 |
| Lau (133) | 18 | HCC | NA | 90Y resin | 99mTc-MAA planar | CT volume + AFP | 120 |
| Strigari (134) | 73 | HCC | 5.8 (1.6–15.6) | 90Y resin | 90Y SPECT | 50% TCP (PR + CR) | 150 |
| Flamen (135) | 8 | Colorectal | 781 mL (95% CI, 332–1,230) | 90Y resin | 99mTc-MAA SPECT | 18F-FDG PET res. > 50% | 46 |
| Song (136) | 23 | HCC and metastases | 467 mL (5–1,400) | 90Y resin | 90Y PET/CT | PFS, RECIST | 200 |
| Chansanti (97) | 15 | NET | 3.9 (±2.3) | 90Y resin | 99mTc-MAA SPECT/CT | mRECIST (PR + CR) | 191 |
| Allimant (137) | 38 | HCC | 5 (2.8–11.4) | 90Y resin | 90Y PET/CT | PFS, mRECIST | Area under DVH > 61 Gy |
| Hermann (138) (SARAH trial) | 121 | HCC | 152 cm (IQR, 46.4–399.5) | 90Y resin | 99mTc-MAA SPECT/CT | RECIST | 100 |
HCC = hepatocellular carcinoma; MAA = macroaggregated albumin; PFS = progression-free survival; EASL = European Association for the Study of the Liver; PR = partial response; CR = complete response; res. = response; TCP = tumor control probability measure of tumor control (typically a radiobiologically derived parameter based on linear quadratic model that accounts for nonuniformity in absorbed dose within tumor and effect this has on likelihood of tumor control; can also be obtained using statistical data–driven models [MIRD Primer and International Commission on Radiation Units and Measurements report 96]); AFP = α-fetoprotein; NA = not applicable; DVH = dose-volume histogram; IQR = interquartile range.
Data in parentheses are ranges.